BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Diagnosis
1419 results:

  • 1. Myelodysplastic Neoplasms (mds): The Current and Future Treatment Landscape.
    Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
    Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Myeloid neoplasms post cytotoxic therapy: epidemiology, pathogenesis outcomes, prognostic factors, and treatment options.
    Ma J; Wang Y
    Ann Med; 2024 Dec; 56(1):2329132. PubMed ID: 38608646
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
    Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Yu SC; Liu MC; Yuan CT; Yang YT; Chuang MK; Ko BS; Tang JL; Sun HI; Chuang YK; Tien HF; Hou HA; Chou WC
    Blood Cancer J; 2024 Apr; 14(1):57. PubMed ID: 38594285
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations.
    Ng AP; Adams R; Tiong IS; Seymour L; Talaulikar D; Palfreyman E; Enjeti A; Tate C
    Pathology; 2024 Jun; 56(4):459-467. PubMed ID: 38580613
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Construction and experimental validation of a novel ferroptosis-related gene signature for myelodysplastic syndromes.
    Zhu Y; He J; Wei R; Liu J
    Immun Inflamm Dis; 2024 Apr; 12(4):e1221. PubMed ID: 38578040
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms.
    Dussiau C; Comont T; Knosp C; Vergnolle I; Bravetti C; Canali A; Houvert A; Largeaud L; Daveaux C; Zaroili L; Friedrich C; Boussaid I; Zalmai L; Almire C; Rauzy O; Willems L; Birsen R; Bouscary D; Fontenay M; Kosmider O; Chapuis N; Vergez F
    Leukemia; 2024 May; 38(5):1131-1142. PubMed ID: 38575672
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Study of a patient with Myelodysplastic/myeloproliferative neoplasm with co-morbid neutrophilia and a novel NCOR1::GLYR1 fusion gene].
    Lei Y; Zhao X; Zhao H; Cheng Y; Wang S; Li J; Zhu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):404-410. PubMed ID: 38565504
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Tripartite prehabilitation of patients with acute myeloid leukaemia and high-risk myelodysplastic syndromes during intensive chemotherapy before allogeneic haematopoietic stem cell transplantation (COHABILIT): protocol for an innovating prospective multicentre study.
    Saillard C; Cuvelier S; Villaron-Goetgheluck C; Boher JM; Almeida-Lopez L; Le Corroller AG; Denis P; Rivieccio C; Calvin S; Vey N; Bannier-Braticevic C
    BMJ Open; 2024 Mar; 14(3):e076321. PubMed ID: 38553062
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
    Bazinet A; Kantarjian H; Bataller A; Pemmaraju N; Borthakur G; Chien K; Alvarado Y; Bose P; Jabbour E; Yilmaz M; DiNardo C; Issa G; Montalban-Bravo G; Short N; Sasaki K; Bull-Linderman D; Daver N; Garcia-Manero G; Ravandi F; Kadia T
    Lancet Haematol; 2024 Apr; 11(4):e287-e298. PubMed ID: 38548404
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Phenotypic Analysis of Hematopoietic Stem and Progenitor Cell Populations in Acute Myeloid leukemia Based on Spectral Flow Cytometry, a 20-Color Panel, and Unsupervised Learning Algorithms.
    Matthes T
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474094
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy.
    Lao Z; Ding LW; Sun QY; Jia L; Yan B; Ng AY; Capinpin SM; Wang R; Ying L; Chng WJ; Koeffler HP; Koh WP; Yuan JM; Yang H; Goh YT; Grigoropoulos N
    Clin Cancer Res; 2024 May; 30(10):2170-2180. PubMed ID: 38437679
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. From Histiocytoid Sweet Syndrome to Myelodysplasia Cutis: History and Perspectives.
    Vignon-Pennamen MD; Battistella M
    Dermatol Clin; 2024 Apr; 42(2):209-217. PubMed ID: 38423682
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.
    Awidi A; Alzu'bi M; Odeh N; Alrawabdeh J; Al Zyoud M; Hamadneh Y; Bawa'neh H; Magableh A; Alshorman A; Al-Fararjeh F; Aladily T; Zeidan AM
    JCO Glob Oncol; 2024 Feb; 10():e2300281. PubMed ID: 38422464
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Applications of Circulating Tumor DNA in Myelodysplastic Syndromes and Acute Myeloid leukemia: Promises and Challenges.
    Xue Y; Xia X; Liu X; Zheng Y; Gu H; Wang X
    Front Biosci (Landmark Ed); 2024 Feb; 29(2):86. PubMed ID: 38420833
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Clinical Relevance of Differential
    Kalitin N; Dudina G; Kostritsa N; Sivirinova A; Vaiman A; Karamysheva A
    In Vivo; 2024; 38(2):657-664. PubMed ID: 38418133
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Bone marrow histology of cytopenias : Contribution to hematological differential diagnosis].
    Kreipe H
    Pathologie (Heidelb); 2024 Mar; 45(2):148-158. PubMed ID: 38381371
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.
    Elghetany MT; Patnaik MM; Khoury JD
    Leuk Res; 2024 Feb; 137():107441. PubMed ID: 38301422
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
    Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roué G; Valcárcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellström-Lindberg E; Solé F; Esteller M
    Cancer Res Commun; 2024 Feb; 4(2):365-377. PubMed ID: 38300528
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Validation of a novel algorithm with a high specificity in ruling out mds.
    Schulz F; Nachtkamp K; Oster HS; Mittelman M; Gattermann N; Schweier S; Barthuber C; Germing U
    Int J Lab Hematol; 2024 Jun; 46(3):510-514. PubMed ID: 38284270
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Nabergoj M; Eikema DJ; Koster L; Platzbecker U; Sockel K; Finke J; Kröger N; Forcade E; Nagler A; Eder M; Tischer J; Broers AEC; Kuball J; Wilson KMO; Hunault-Berger M; Collin M; Russo D; Corral LL; Helbig G; Mussetti A; Scheid C; Gurnari C; Raj K; Drozd-Sokolowska J; Yakoub-Agha I; Robin M; McLornan DP
    Bone Marrow Transplant; 2024 Mar; 59(3):395-402. PubMed ID: 38195984
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 71.